Halozyme: Breast Cancer Drug Herceptin SC Gets Marketing Authorization In EU

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the European Commission has granted Roche Holding AG (RHHBY.PK) European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for treating HER2-positive breast cancer.

This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20). It is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form.

The approval was based on data from the HannaH study which showed that the subcutaneous formulation of Herceptin was associated with comparable efficacy to Herceptin administered intravenously in women with HER2-positive early breast cancer. It resulted in non-inferior trastuzumab plasma levels.

Overall, the safety profile in both arms of the HannaH study was consistent with that expected from standard treatment with Herceptin and chemotherapy in this setting. No new safety signals were identified.

Gregory Frost, CEO of Halozyme, said, ''This approval is great news for the more than 80,000 patients who receive treatment with Herceptin each year in the EU. The reduced administration time and enhanced convenience may enable patients in the EU to spend less time in the hospital while also increasing efficiency for physicians and other health care providers."